PharmEvolution, the Vth International Forum for Pharmaceutical Industry Development in Russia, was opened on April 23, 2019 in Innovation Culture Center, Kaluga. The forum was attended by representatives of global pharmaceutical companies, heads of government institutions, representatives of R&D businesses and innovative business incubators, trade associations, unions, foundations, as well as lead analysts, investors and experts.
The list of key forum subjects includes the government industry development strategy and in inception by business community, new legislation initiatives related to the pharmaceutical industry, government export strategy, pharmaceuticals’ marking, digitalization in pharmaceutical industry, personnel training for pharmaceutical clusters, R&D best practices in Russia and the development of such practices.
Anatoly Artamonov, Kaluga Region Governor, delivered a welcoming speech. He noted that Kaluga pharmaceutical cluster was to manufacture over 200 pharmaceuticals by the end of 2019. Two new production facilities, which are to manufacture finished dosage forms, are to be commissioned this year. The plants are owned by Russian companies, namely Pharm-Sintez and Sfera-Pharm. Anatoly Artamonov said: “Kaluga Region has developed an efficient dual education system to train personnel for the pharmaceutical industry. The Center for Practical Training established at the Medical Faculty of Obninsk Nuclear Energy Institute, provides both specialists’ training and retraining services. Hemopharm has implemented a unique project in 2019 launching a scholarship program to support students trained for Kaluga pharmaceutical cluster and demonstrating good results in the field of education and research. The company has selected nine students and pays scholarship allowance to them.
Kaluga pharmaceutical cluster is one of the largest clusters of its kind in the Russian Federation. Sixty four entities, including global and Russian pharmaceutical companies, innovative SMEs, leading R&D and education centers are members of the cluster.
Alexey Alekhin, the Head of Department for Pharmaceutical and Medicine Industry of the Ministry of Industry and Trade of the Russian Federation, noted, that the pharmaceutical industry had demonstrated good progress in the recent years. He noted: “The pharmaceutical industry demonstrates production growth, the share of locally produced pharmaceuticals grows both in the market in general and in government procurement in particular. Businesses expand their export potential. The Ministry of Industry and Trade of the Russian Federation develops additional measures to support exporters. Companies may get monetary funds on beneficial terms to implement export projects.
Alexey Alekhin highly appreciated the efficiency of measures implemented by Kaluga Region Government in the field of personnel training for the pharmaceutical industry.
Sune Mohr, Vice President, Novo Nordisk Kaluga, said that the pharmaceutical business was an inseparable element of the Russian Federation national strategies in the fields of healthcare and drugs production. He said: “The pharmaceutical industry makes the most important contribution to successful implementation of the Russian Government’s Pharma 2020 strategy and Pharma 2030 strategy being currently under development. Novo Nordisk has launched full cycle production of modern insulins in September 2018 at its Kaluga plant. Almost 5 million Russian patients now have access to modern insulins previously unavailable in this country”.
Irina Ivanisheva, Director, Corporate Relations and Legal Issues, AstraZeneca (Russia and Eurasia), said: “AstraZeneca commissioned its production facility in Kaluga Region in Kaluga in 2015. Currently technology transfer process in underway. In the near future the plant is to launch full cycle production of unique pharmaceuticals manufactured at 2-3 other AstraZeneca sites. This clearly demonstrates the degree of confidence in Russia and Russian specialists”.
AstraZeneca is an international innovative biopharmaceutical company operating in more than 100 countries of the world. The company views Russia as a top priority market and strives to shape and develop its local competences in the area of pharmaceuticals development and production, expanding its portfolio of innovative medicines to be offered to Russian patients.
PharmEvolution is organized by the Government of Kaluga Region, the Agency for Innovative Development – Center for Cluster Development of Kaluga Region, the Agency for Regional Development of Kaluga Region with the support of Kaluga pharmaceutical cluster and Kommersant Publishers. PharmEvolution partner: Novo Nordisk, the leader in diabetes treatment. The forum is supported by Sberbank of Russia JSC, Kaluga branch.
Information on Kaluga Pharmaceutical Cluster:
Kaluga pharmaceutical cluster is the first Russian cluster to receive Silver Certificate by the European Secretariat for Cluster Analysis. The cluster management system as well as key business areas were audited by 30 parameters using European Cluster Excellence Initiative evaluation methodology. Over 70% of the Kaluga pharmaceutical cluster audited parameters were significantly exceeded, which confirms high efficiency of its management system and the cluster’s compliance with global best practices.
In October 2016 Kaluga pharmaceutical cluster joined top priority project implemented by the Ministry for Economic Development of the Russian Federation named Development of Innovative Clusters, Investment Attractiveness Leaders.
Kaluga pharmaceutical cluster’s strategic objective is to join Top 3 largest Russian pharmaceutical clusters in terms of market share. According to existing forecasts in 2020 its share is to reach 10-12%.